CORRECTION: Cannabis and Biotech Firms Set to Explode
HENDERSON, NV / ACCESSWIRE / July 31, 2018 / Biotech and Cannabis companies are starting to heat up once again. We have identified two companies that could greatly benefit from the action!
Everyone should start researching this undiscovered company right away, BRTX (BioRestorative Therapies, Inc.). BRTX is on the cusp of receiving major attention from the street. As BRTX prepares for it’s Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar currently, but that could all change in the blink of an eye. BRTX presents an incredible opportunity to investors that will have discovered the company before BRTX starts it’s phase 2 clinical trial using BRTX-100. The company just made an addition to their scientific advisory board, and more positive news could be on the way!
These two companies could benefit from increased attention in their respective sectors and industry: BioRestorative Therapies, Inc. (BRTX), and CV Sciences, Inc. (OTCQB: CVSI)
BioRestorative Therapies, Inc. (BRTX)
Market Cap: $10.57M Share Price: $1.59
BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, recently announced the appointment of Jason S. Lipetz, M.D. to the Company’s Scientific Advisory Board. Dr. Lipetz has an impressive resume and will certainly add clinical expertise as the Company prepares for its Phase 2 trial using BRTX-100 to treat chronic lumbar disc disease. So far the stock has been trading sideways, announcements like these many times lead to more news in the near future. Investors should monitor this situation closely.
CV Sciences, Inc. (OTCQB: CVSI)
Market Cap: $262.0M Share Price: $2.89
CV Sciences, Inc. is a supplier and manufacturer of hemp-based phytocannabinoids including cannabidiol (CBD) oil and developer of specialty pharmaceutical therapeutics. The Company recently had news showing unaudited second quarter 2018 revenue. Second quarter 2018 revenue is expected to be USD 12.3 Million, up over 200% to the second quarter of 2017.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and seven thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.
For Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communication, LLC
ReleaseID: 507509